PTPIP51 activators form a distinct category of biochemical agents that engage with the Protein Tyrosine Phosphatase Interacting Protein 51 (PTPIP51). PTPIP51 is a multifaceted protein implicated in a wide range of cellular processes, including regulation of cell growth, differentiation, and apoptosis, primarily through its interactions with various signaling proteins. The activators of PTPIP51 are designed to modulate its activity, potentially affecting the signaling pathways in which PTPIP51 is involved. They may exert their influence by binding to PTPIP51 and inducing a conformational change that increases its interaction with its protein partners, such as the protein tyrosine phosphatases (PTPs) and kinases, which are pivotal in cellular signaling.
The structural complexity of PTPIP51 activators is likely varied, encompassing numerous potential chemotypes that can engage with the protein's active sites or allosteric sites to modulate its function. The design of these molecules typically relies on a deep understanding of the protein's structure and the critical regions necessary for its activation. High-throughput screening, coupled with advanced computational modeling, can identify candidate molecules that interact with PTPIP51. Subsequent steps usually involve iterative chemical synthesis and structure-activity relationship (SAR) analysis to refine the potency and selectivity of these activators. As research tools, PTPIP51 activators can illuminate the protein's role in cellular signaling networks, helping to delineate the intricate web of intracellular communication. Their use can provide insights into the underlying molecular mechanisms that govern cell function and the complex interplay between different signaling molecules.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
By inhibiting PI3K and subsequently reducing Akt pathway activity, LY294002 can elevate the levels of unphosphorylated PTPIP51, favoring its active form. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which can lead to a shift in cellular growth mechanisms, increasing the reliance on and activation of PTPIP51. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A sc-24000B sc-24000C | 10 µg 100 µg 500 µg 1 mg | $160.00 $750.00 $1400.00 $3000.00 | 59 | |
By inhibiting protein phosphatases, Calyculin A maintains proteins in a phosphorylated state, potentially leading to increased PTPIP51 activation through sustained phosphorylation. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Similar to Calyculin A, Okadaic Acid maintains PTPIP51 in its phosphorylated, potentially more active state, by inhibiting protein phosphatases. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin raises cAMP levels, stimulating protein kinase A (PKA). Activated PKA can phosphorylate and activate various proteins, indirectly enhancing PTPIP51 activation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
By inhibiting HDAC and altering gene expression, Trichostatin A can lead to an upregulation of pathways that necessitate PTPIP51 activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK, leading to reduced ERK pathway activity. Reduced ERK activity can result in elevated levels of active, unphosphorylated PTPIP51. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
By inhibiting p38 MAPK, SB203580 could shift cellular signaling reliance to pathways that involve and activate PTPIP51. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
Inhibiting JNK with SP600125 could lead to a compensatory activation of pathways that rely on PTPIP51, increasing its activation. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin activates JNK and p38 MAPK pathways, which could indirectly upregulate PTPIP51 activity due to its interactions within these pathways. |